Protara Therapeutics, Inc. (TARA) announced positive results on Friday from a three-month evaluation of carcinoma in situ patients undergoing treatment with TARA-002, the company's experimental cell-based therapy. Following this news the stock is up 20% in the pre-market.
The ongoing clinical program focuses on high-risk non-muscle invasive bladder cancer patients, including those who are Bacillus Calmette-Guérin-unresponsive, BCG-experienced, and BCG-naïve.
TARA-002 showed a 43 percent complete response rate at three months in BCG-Unresponsive/Experienced patients and a 63 percent complete response rate in CIS-only patients in the NMIBC program.
The therapy also demonstrated a favorable safety profile without any severe treatment-related adverse events.
The company plans to release preliminary data from the six-month evaluation of patients in the ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer in the second half of 2024.
In pre-market activity on the Nasdaq, the shares were trading at $4.86, up 20.89%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.